story of the week
RAF1 Amplification Drives a Subset of Bladder Tumors and Confers Sensitivity to MAPK-Directed Therapeutics
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Journal of Clinical Investigation
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeutics
J. Clin. Invest. 2021 Sep 23;[EPub Ahead of Print], RT Bekele, AS Samant, AH Nassar, J So, EP Garcia, CR Curran, JH Hwang, DL Mayhew, A Nag, AR Thorner, J Börcsök, Z Sztupinszki, CX Pan, J Bellmunt, DJ Kwiatkowski, GP Sonpavde, EM Van Allen, KW MouwFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.